- 54% YoY Revenue Growth: Q2 FY2026 revenue reached $4.1 million, up 54% year-over-year.
- 65% Gross Margin Expansion: Gross profit surged to $2.7 million (65% margin), doubling from $1.4 million in the same period last year.
- $14.3M Divestiture Proceeds: Net proceeds from Netherlands wet lab divestiture strengthened cash reserves to $16.5 million.
- GLP1 Receptor Agonist Advancement: LensAI-designed compounds outperformed semaglutide in third-party in vitro assays.
Operational Highlights and Strategic Progress
The company made significant progress in its internal programs, advancing its GLP1 and longevity programs using LensAI and HYFT patterns. The dengue vaccine initiative also continued to move forward, leveraging pathogen-specific HYFT logic. Additionally, MindWalk divested its non-core wet lab operations in the Netherlands, generating $14.3 million in net proceeds and strengthening its balance sheet.
Valuation Metrics and Future Prospects
Analyzing MindWalk's valuation metrics, the P/S Ratio stands at 5.24, while the P/E Ratio is -3.47, indicating that the market has already priced in significant growth expectations. The ROE and ROIC are -140.47% and -50.01%, respectively, highlighting the company's current unprofitability. Analysts estimate next year's revenue growth at -28.9%, suggesting a potential decline in growth momentum. With a strengthened balance sheet and a clear strategy, MindWalk is poised to continue investing in its HYFT-powered platform, internal programs, and commercial initiatives.
Capital Deployment and Future Plans
MindWalk plans to utilize the proceeds from the divestiture and potential future fundraising to invest in commercial initiatives, R&D, and the development of its assets. The company is also exploring a segregated portfolio structure for its AI-driven pipeline, aiming to protect existing investors against dilution. With a focus on deploying capital directly into its assets, MindWalk is working to compound its strategic advantage and drive future growth.